
CAR T Cell Therapy Evolves: From Blood Cancer Success to Solid Tumor Challenges
CAR T cell therapy has transformed blood cancer treatment, achieving high survival rates, but faces hurdles in cost, side effects, and expanding to solid tumors. Recent FDA approvals for myeloma and myeloproliferative disorders highlight broader immunotherapy advances, while experts debate next-generation designs and accessibility.













